Dr Sebastian Robert Stanciu, MD | |
2122 University Blvd S, Jacksonville, FL 32216-8937 | |
(904) 398-5614 | |
(904) 398-5617 |
Full Name | Dr Sebastian Robert Stanciu |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 25 Years |
Location | 2122 University Blvd S, Jacksonville, Florida |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1730145608 | NPI | - | NPPES |
G099441597 | Other | GA | GEORGIA MEDICARE PALMETTO GBA |
273691800 | Medicaid | FL |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RI0200X | Internal Medicine - Infectious Disease | ME89939 (Florida) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Baptist Health Medical Center - Jacksonville | Jacksonville, FL | Hospital |
Orange Park Medical Center | Orange park, FL | Hospital |
Mayo Clinic Health System In Waycross | Waycross, GA | Hospital |
Memorial Hospital Jacksonville | Jacksonville, FL | Hospital |
Ascension St Vincent's Riverside | Jacksonville, FL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
First Coast Infectious Disease Consultants Llc | 2567551104 | 18 |
Georgia Infectious Disease Consultants | 3779822952 | 2 |
News Archive
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
A new study presented at the Society for Healthcare Epidemiology of America has demonstrated that the trophon EPR is the only high level disinfection system proven to kill natural, infectious, high-risk human papilloma virus (HPV) under normal use conditions.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that it has begun European distribution of PerClot®, a novel polysaccharide hemostatic agent used to control bleeding during surgical procedures or following traumatic injuries.
A new year is a time for reprioritizing. To encourage consumers to make their eyes a priority this year, AllAboutVision.com has issued its 2012 Checklist for Better Vision & Eye Health.
Grocery shoppers in a new study report that a one to 100-point food rating system would help them choose what goes into their carts.
› Verified 6 days ago
Entity Name | First Coast Infectious Disease Consultants Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1740477843 PECOS PAC ID: 2567551104 Enrollment ID: O20071204000531 |
News Archive
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
A new study presented at the Society for Healthcare Epidemiology of America has demonstrated that the trophon EPR is the only high level disinfection system proven to kill natural, infectious, high-risk human papilloma virus (HPV) under normal use conditions.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that it has begun European distribution of PerClot®, a novel polysaccharide hemostatic agent used to control bleeding during surgical procedures or following traumatic injuries.
A new year is a time for reprioritizing. To encourage consumers to make their eyes a priority this year, AllAboutVision.com has issued its 2012 Checklist for Better Vision & Eye Health.
Grocery shoppers in a new study report that a one to 100-point food rating system would help them choose what goes into their carts.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Sebastian Robert Stanciu, MD Po Box 55009, Jacksonville, FL 32216-0009 Ph: (912) 335-6943 | Dr Sebastian Robert Stanciu, MD 2122 University Blvd S, Jacksonville, FL 32216-8937 Ph: (904) 398-5614 |
News Archive
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
A new study presented at the Society for Healthcare Epidemiology of America has demonstrated that the trophon EPR is the only high level disinfection system proven to kill natural, infectious, high-risk human papilloma virus (HPV) under normal use conditions.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that it has begun European distribution of PerClot®, a novel polysaccharide hemostatic agent used to control bleeding during surgical procedures or following traumatic injuries.
A new year is a time for reprioritizing. To encourage consumers to make their eyes a priority this year, AllAboutVision.com has issued its 2012 Checklist for Better Vision & Eye Health.
Grocery shoppers in a new study report that a one to 100-point food rating system would help them choose what goes into their carts.
› Verified 6 days ago
Dr. Jami Ann Rothe Kinnucan, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4500 San Pablo Rd S, Jacksonville, FL 32224 Phone: 904-953-2000 | |
Michelle Tulang, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4500 San Pablo Rd S, Jacksonville, FL 32224 Phone: 904-953-2000 | |
Dr. Minnsun Koh Park, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3900 University Blvd S, Jacksonville, FL 32216 Phone: 904-222-6656 | |
Sandrela Mussallam Abu Shaibeh, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 820 Prudential Dr Ste 304, Jacksonville, FL 32207 Phone: 904-202-3860 Fax: 904-202-3846 | |
Krunal Patel, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4800 Belfort Rd, Jacksonville, FL 32256 Phone: 904-398-7205 Fax: 904-396-4047 | |
Zaid Abdel Rahman, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 4500 San Pablo Rd S, Jacksonville, FL 32224 Phone: 904-953-2000 | |
Sina O'sullivan, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4500 San Pablo Rd S, Jacksonville, FL 32224 Phone: 904-953-2000 |